Deucravacitinib in Active Psoriatic Arthritis: Efficacy and Safety up to 52 Weeks From the Randomized, Double-Blind, Phase 3 POETYK PsA-2 Trial - Report - MDSpire

Efficacy and Safety of Deucravacitinib in Patients with Active Psoriatic Arthritis: Results from the Phase 3 POETYK PsA-2 Trial Over 52 Weeks

  • By

  • Philip J. Mease

  • Vinod Chandran

  • April W. Armstrong

  • Ricardo Blanco

  • Alexis Ogdie

  • Evan L. Siegel

  • Alice B. Gottlieb

  • Xiaofeng Zeng

  • Diamant Thaçi

  • Mitsumasa Kishimoto

  • Hendrik Schulze-Koops

  • Alan Kivitz

  • Eva Dokoupilová

  • Akimichi Morita

  • Eric M. Ruderman

  • Michael Plewinski

  • Kejia Wang

  • Caroline Sardinas

  • Eleni Vritzali

  • John Vaile

  • Atul Deodhar

  • July 20, 2026

Share

Clinical Report: Efficacy and Safety of Deucravacitinib in Psoriatic Arthritis

Overview

The Phase 3 POETYK PsA-2 trial demonstrated that deucravacitinib significantly improved disease activity in patients with active psoriatic arthritis over 52 weeks compared to placebo. The treatment was well-tolerated, with no new safety signals identified.

Background

Psoriatic arthritis (PsA) is a chronic inflammatory disease that can lead to joint damage and disability. Effective management is crucial for improving patient outcomes and quality of life. Deucravacitinib, a selective TYK2 inhibitor, represents a new therapeutic option for patients with active PsA.

Data Highlights

OutcomeDeucravacitinibPlacebo
ACR20 at Week 1654.2%39.4%
PASI75 at Week 1640.9%15.4%
MDA at Week 1625.6%14.7%

Key Findings

  • Deucravacitinib achieved ACR20 in 54.2% of patients at week 16 compared to 39.4% with placebo.
  • PASI75 response was 40.9% for deucravacitinib versus 15.4% for placebo at week 16.
  • Minimal disease activity (MDA) was reached by 25.6% of patients on deucravacitinib compared to 14.7% on placebo at week 16.
  • Improvements in HAQ-DI and SF-36 PCS were noted with deucravacitinib treatment.
  • Safety profile through week 52 showed few serious adverse events and no new safety signals.

Clinical Implications

The findings from the POETYK PsA-2 trial support the use of deucravacitinib as an effective treatment option for patients with active psoriatic arthritis. Clinicians may consider this therapy for patients who have not responded adequately to other treatments.

Conclusion

Deucravacitinib demonstrates significant efficacy and a favorable safety profile in the treatment of active psoriatic arthritis over 52 weeks, providing a new therapeutic option for patients.

Related Resources & Content

  1. Mease PJ, et al., Phase 3 POETYK PsA-2 Trial -- Efficacy and Safety of Deucravacitinib
  2. conexiant — ​​​​​​​PsA Treatment Options Expand
  3. Journal of Crohn's and Colitis — Deucravacitinib in patients with inflammatory bowel disease: 12-week efficacy and safety results from 3 randomized phase 2 studies in Crohn’s disease and ulcerative colitis
  4. Dermatology and Therapy — Risankizumab versus Deucravacitinib in Adults With Moderate Plaque Psoriasis: 16-Week Results from the Phase 4 IMMpactful Trial
  5. Clinical Rheumatology — Effectiveness of Certolizumab Pegol With and Without Disease-Modifying Anti-Rheumatic Drugs Over Four Years in Patients with Psoriatic Arthritis: Findings from the RAPID-PsA Randomized Controlled Trial
  6. PsA Treatment Options Expand
  7. Deucravacitinib in patients with inflammatory bowel disease
  8. Risankizumab versus Deucravacitinib in Adults With Moderate Plaque Psoriasis
  9. https://mjrheum.org/assets/files/792/file556_2024.pdf
  10. EULAR Abstract Archive

Original Source(s)

Deucravacitinib in Active Psoriatic Arthritis: Efficacy and Safety up to 52 Weeks From the Randomized, Double-Blind, Phase 3 POETYK PsA-2 Trial

  • by Philip J. Mease, Vinod Chandran, April W. Armstrong, Ricardo Blanco, Alexis Ogdie, Evan L. Siegel, Alice B. Gottlieb, Xiaofeng Zeng, Diamant Thaçi, Mitsumasa Kishimoto, Hendrik Schulze-Koops, Alan Kivitz, Eva Dokoupilová, Akimichi Morita, Eric M. Ruderman, Michael Plewinski, Kejia Wang, Caroline Sardinas, Eleni Vritzali, John Vaile, Atul Deodhar

  • July 20, 2026

Related Content

Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity

When Bad Data Enters the Drug Pipeline

Federal prosecutors allege that a Florida physician and research staff fabricated clinical trial records that were submitted into database systems used to evaluate investigational drugs.

Comparative treatment persistence of upadacitinib vs. tofacitinib in psoriatic arthritis: a multicenter observational study from the BIRRA cohort